New York State Common Retirement Fund Sells 1,000 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

New York State Common Retirement Fund lowered its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 8.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,075 shares of the medical research company’s stock after selling 1,000 shares during the quarter. New York State Common Retirement Fund’s holdings in Bio-Rad Laboratories were worth $3,638,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Venturi Wealth Management LLC lifted its position in Bio-Rad Laboratories by 2,175.0% during the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 87 shares during the last quarter. Gladius Capital Management LP bought a new position in Bio-Rad Laboratories during the third quarter valued at $32,000. Asset Planning Inc bought a new position in Bio-Rad Laboratories during the fourth quarter valued at $33,000. UMB Bank n.a. lifted its position in Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 32 shares during the last quarter. Finally, Point72 Hong Kong Ltd bought a new position in Bio-Rad Laboratories during the third quarter valued at $55,000. Institutional investors own 65.24% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on BIO. Royal Bank of Canada restated an “outperform” rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Wells Fargo & Company lowered their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. Finally, StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Trading Down 0.4 %

BIO stock opened at $264.60 on Friday. The company has a market capitalization of $7.41 billion, a PE ratio of -4.07 and a beta of 0.90. Bio-Rad Laboratories, Inc. has a 12 month low of $262.11 and a 12 month high of $387.99. The firm’s 50-day moving average is $327.02 and its 200 day moving average is $332.52. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.